Condition: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · Primary Mediastinal Large B-Cell Lymphoma · Sponsor: Academic and Community Cancer Research United
This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. Epcoritamab is a bispecific antibody. It works by simultaneously attaching to a molecule called CD20 on cancerous B-cells and a molecule called CD3 on effector T-cells, which are a type of immune cell. When epcoritamab binds to CD20 and CD3, it brings the two cells together and activates the T-cells to kill the cancerous B-cells. Epcoritamab may increase a patient's chances of achieving complete remission after CD19-directed CAR-T therapy, compared to standard observation.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Mayo Clinic in Rochester | Rochester, Minnesota, United States | Not Yet Recruiting |
| Siteman Cancer Center at Washington University | St Louis, Missouri, United States | Not Yet Recruiting |
| Hackensack University Medical Center | Hackensack, New Jersey, United States | Not Yet Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Not Yet Recruiting |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill, North Carolina, United States | Not Yet Recruiting |
| Huntsman Cancer Institute/University of Utah | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06238648